Campbell & CO Investment Adviser LLC Coherus Bio Sciences, Inc. Transaction History

Campbell & CO Investment Adviser LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	BUY	$3.74 - $5.45 $202,816 - $295,548	54,229 New	54,229 $202,000
Q3 2022 Nov 14, 2022	SELL	$7.17 - $13.87 $50,405 - $97,506	-7,030 Reduced 26.07%	19,934 $192,000
Q2 2022 Aug 09, 2022	BUY	$5.86 - $13.23 $158,009 - $356,733	26,964 New	26,964 $195,000
Q1 2021 May 14, 2021	SELL	$14.42 - $21.39 $176,010 - $261,086	-12,206 Closed	0 $0
Q4 2020 Feb 09, 2021	SELL	$16.56 - $18.94 $86,112 - $98,488	-5,200 Reduced 29.87%	12,206 $212,000
Q3 2020 Oct 15, 2020	BUY	$17.41 - $19.89 $74,863 - $85,527	4,300 Added 32.81%	17,406 $319,000
Q2 2020 Jul 29, 2020	BUY	$14.43 - $19.16 $189,119 - $251,110	13,106 New	13,106 $234,000
Q1 2020 Apr 29, 2020	SELL	$11.67 - $22.53 $217,832 - $420,544	-18,666 Closed	0 $0
Q4 2019 Jan 23, 2020	SELL	$16.33 - $21.37 $1,584 - $2,072	-97 Reduced 0.52%	18,666 $336,000
Q3 2019 Oct 16, 2019	BUY	$16.3 - $23.37 $60,815 - $87,193	3,731 Added 24.82%	18,763 $380,000
Q2 2019 Jul 10, 2019	BUY	$13.1 - $22.1 $196,919 - $332,207	15,032 New	15,032 $332,000

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.